Molecular Imaging of Neuroendocrine Tumors by Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology University Hospital Uppsala, Sweden
|
|
|
- Hollie Johnson
- 7 years ago
- Views:
Transcription
1 Molecular Imaging of Neuroendocrine Tumors by Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology University Hospital Uppsala, Sweden Singapore November 2012
2 Diagnostic problems Small tumors Staging Early detection of residual disease or recurrence Treatment effects Tumor biology
3 Neuroendocrine tumors PET (FDG) Modlin 2008
4 Molecular Imaging Functional techniques Octreoscan (somatostatin receptor scintigraphy) MIBG-scintigraphy (metaiodobenzylguanidine) PET (positron emission tomography) ( 11 C-5-HTP, 18 F-DOPA, 68 Ga-Dotaoctreotide 99 Tc EDDA-HYNIC-TOC)
5 Receptor Scintigraphy Neuroendocrine tumors 111 In Octreotide - SST2 (SST5) receptor ligands - Sensitivity: % Courtesy A Kjaer
6 Carcinoid tumor
7 Octreoscan
8 111 In Octreotide ( 111 In-DTPAOC) Bindereup T et al. JNM 2010
9 Neuroendocrine tumors have unique characteristics: Uptake of hormone precursors (tryptophan) Synthesize, store, and release hormones (catecholamines, serotonin) Express specific receptors and transporters (somatostatin receptors, norepinephrine transporter system) Pearse AGE. The APUD concept and hormone production, 1968, 1969, 1980: Amine Precursor Uptake and Decarboxylation.
10 Serotonin turnover in neuroendocrine cells Peptide receptors 11 C-5HIAA 5-HIAA MAO Serotonin Trh 11 C-HTP AADC Serotonin 11 C-serotonin Tryptophan 11 C-HTP Auto-receptors
11 Why PET?
12 Molecular Prolifing
13 Positron emitting radionuclide 511 kev photon Positron Electron 511 kev photon
14
15 Specific isotopes for NETs 11 C-5HTP (hydroxytryptophan) 11 C-Dopamine 18 F-Dopamine 68 Ga-Dota Octreotide 99 Tc EDDA-HYNIC-octreotide [Lys40(Ahx-DTPA- 111 In)NH2]- Exendin-4 (GLP-1)
16 11 C-5-HTP-PET
17 CT PET PET/CT
18 11 C-5-HTP-PET of a patient with elevated gastrin levels showing a duodenal gastrinoma not detected by other methods
19 PET/CT with 11 C-5-HTP
20
21
22
23 Results Tumors were imaged by PET in 95% (36/38) SRS in 84% (32/38) CT in 79% (30/38) More lesions were detected with PET than with SRS and CT in 58% and equal number in 34% The primary tumors (PT) were imaged by PET in 84% (16/19) SRS in 58% (11/19) CT in 47% (9/19) Several previously undiagnosed lesions were detected with PET, most in the range of cm (therefore easily overlooked at CT) Orlefors et al. JCEM, 2005
24 Fig 3. (A) Computed tomography (CT) scan, (B) somatostatin receptor scintigraphy (SRS), (C) 18F-dihydroxy-phenyl-alanine (18F-DOPA) positron emission tomography (PET), and (D) 11C-5-hydroxy-tryptophan (11C-5-HTP) PET of a 54-year-old male patient with metastatic islet cell tumor Koopmans, K. P. et al. J Clin Oncol; 26: Copyright American Society of Clinical Oncology
25 Koopmans et al, JCO 2008: 23 patients with endocrine pancreatic tumors (EPT) 24 patients with carcinoid tumors Per-patient sensitivity Carcinoids 11 C-5-HTP PET 100% 18 F-DOPA PET 96% SRS 86% CT 96% EPTs 11 C-5-HTP PET 100% 18 F-DOPA PET 89% SRS 78% CT 87%
26 Whole body FDG-PET Transaxial Frontal projection Sagittal in a poorly differentiated neuroendocrine tumor
27 A, survival distribution among patients in the FDG-PET negative (black, dashed) or FDG-PET positive (black, solid) groups Binderup T et al. Clin Cancer Res 2010;16: by American Association for Cancer Research
28 A, survival distribution among patients with SUVmax below (black, dashed line) or above (black, solid line) 9 Binderup T et al. Clin Cancer Res 2010;16: by American Association for Cancer Research
29 68 Ga-labeled Peptides for PET 68 Ga-DOTATOC Most used SST 2 68 Ga-DOTANOC SST 2, SST 3, SST 5 68 Ga-DOTATATE SST 2 Highest affinity
30 PET/CT with 68 Ga-DOTA-octreotide
31 PET/CT with 68 Ga-DOTA-octreotide
32 PET with 68 Ga-DOTA-octreotide Advantages: no cyclotron required more sensitive than Octreoscan possible to use for radioactive or tumortargeted treatment may be possible to quantify somatostatin receptors - tumor-targeted therapy
33 Treglia et al. Endocrine 2012:42:80-87
34 Diagnostic performance of somatostatin receptor PET or PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours on a per patient-based analysis Treglia et al. Endocrine 2012:42:80-87
35 Summary ROC cure of diagnostic accuracy of Gallium-68 somatostatin receptor PET and PET/CT in thoracic and gastroenteropancreatic neuroendocrine tomours Treglia et al. Endocrine 2012:42:80-87
36
37 64 Cu vs. 68 Ga Zibo, Adv Drug Deliv Rev GA T 1/2 : 68 min Pos. range: 4 mm Generator 68 CU T 1/2 : 13 h Pos. range: 1 mm Cyklotron
38 Same patient new tracer 111 In-DTPAoctreotide 64 Cu-DOTATATE Pfeifer et al. JNM 2012
39 New markers for molecular imaging
40 Conclusion PET-scanning with specific isotopes is the most sensitive and specific imaging technique for NETs Ga 68 - DOTATATE PET will in a near future replace (Octreoscan ) The availability and costs are the limitations today
41 Thank you! Centre of Excellence Endocrine Tumors, Uppsala University C e n t r e o f E x c e l l e n c e E n d o c r i n e T u m o r s endocrinetumors.org
Ga-68 PET. John Buscombe
Ga-68 PET John Buscombe Introduction n Ga-68 a new radionuclide n PET based n Chemistry can be difficult n Used primarily with DOTATATE n Now also used with other agents In-111 octreotide v F-18 FDG in
Peptide receptor radionuclide treatment of neuroendocrine tumours
Peptide receptor radionuclide treatment of neuroendocrine tumours Jann Mortensen Dept. of Clinical Physiology, Nuclear Medicine & PET Neuroendocrine Tumor Center of Excellence Rigshospitalet University
Gastrointestinal and pancreatic neuroendocrine tumours. Dr. med. Henrik Csaba Horváth
Gastrointestinal and pancreatic neuroendocrine tumours Dr. med. Henrik Csaba Horváth What is the definition of neuroendocrine tumours? Neuroendocrine tumours are neoplastic lesions, composed either by
Non-Functioning Pancreatic Neuroendocrine Tumours
Non-Functioning Pancreatic Neuroendocrine Tumours NET Patient Foundation Non-Functioning Pancreatic Neuroendocrine Tumours This booklet is intended to provide patients and their carers with information
Novel Radionuclide Therapies in Oncology : Promising Area in the Field of Nuclear Medicine
Novel Radionuclide Therapies in Oncology : Promising Area in the Field of Nuclear Medicine Erik Mittra, MD, PhD Clinical Assistant Professor Radiology / Nuclear Medicine Objectives / Outline 1. Understand
BEYOND 18 F-FDG: INTRODUCTION TO NEW RADIOPHARMACEUTICALS
BEYOND F-FDG: INTRODUCTION TO NEW RADIOPHARMACEUTICALS Asti Mattia Nuclear Medicine Department Santa Maria Nuova Hospital, Reggio Emilia, Italy SUMMARY: F-Labelled Choline analogues. Comparison between
Neuroendocrine Tumors
Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.
PET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection
PET-CT Can we afford PET-CT John Buscombe New technology Combines functional information-pet anatomical information-ct Machine able to perform both studies in single imaging episode PET imaging depends
A23: Oncologic Disease- Tumor Markers
A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of
Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
Aktualne reguły leczenia nowotworów neuroendokrynnych przewodu pokarmowego
Aktualne reguły leczenia nowotworów neuroendokrynnych przewodu pokarmowego Current treatment options for neuroendocrine GI tumors Archil Aladashvili, GE Current treatment options for neuroendocrine GI
High-Grade Neuroendocrine Tumours. NET Patient Foundation
High-Grade Neuroendocrine Tumours NET Patient Foundation High-Grade Neuroendocrine Tumours (NETs) This booklet is intended to provide patients and their carers with information relating to the diagnosis,
PET/CT: Basic Principles, Applications in Oncology
PET/CT: Basic Principles, Applications in Oncology Mabel Djang, HMS III Overview PET Basics and Limitations PET/CT - Advantages and Limitations Applications of PET/CT in oncology Summary 2 Principles of
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Christopher Martel, M.Sc., CHP Lisa Thornhill,, NRRPT, RT(NM) Boston University Medical Center Thyroid Carcinoma New cases and deaths in
HERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments
Table of Contents Commenters... 1 Public Comments... 2 References Provided by Commenters... 6 Commenters Identification Stakeholder A Medical Imaging & Technology Alliance (MITA), Arlington, VA [Submitted
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Prof. Dr. Chris Verslype, Leuven Prof. Dr. Aurel Perren, Bern Menue Challenges: 1. Gastric NET 2. Appendiceal NET 3. Rectal NET SEER,
False positive PET in lymphoma
False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)
Medical Physics and Radioactivity
Medical Physics and Radioactivity Radioactivity Unstable nucleus Electromagnetic wave particle Atoms which emit electromagnetic radiation or a particle by the spontaneous transformation of their nucleus
SPECT and PET imaging in porcine inflammation and infection models. UCPH pig model network seminar
SPECT and PET imaging in porcine inflammation and infection models UCPH pig model network seminar Friday November 21. 2014, 8.30 12.00, auditorium A2 70.02, Thorvaldsensvej 40, 1871 Frederiksberg C. See
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
PET and PET/CT in Clinical Trials
PET and PET/CT in Clinical Trials Nathan C. Hall, M.D., Ph.D. The Ohio State University Medical Center CALGB Imaging Core Lab CALGB Imaging Committee Outline Introduction to PET Positron Emitter Physics
PET/CT in Lymphoma. Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto
PET/CT in Lymphoma Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto Outline 1. Introduction: PET/CT, how does it work? 2.Current
Thursday, November 3, 2005
Thursday, November 3, 2005 8:30-10:30 a. m. Gastric Tumors, Session 1 Chairman: P. Ruszniewski, Clichy, France 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders: G. Rindi, Parma,
PET Imaging of Hypoxia
PET Imaging of Hypoxia John Humm, PhD Dept. of Medical Physics MSKCC AAPM Session: Introduction to Cancer Biology Tuesday 20 th July Many strong hypoxia radiotracer imaging programs University of Washington
In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer
In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer Prostate cancer is the second most common cancer in men worldwide, accounting for 15% of all new cancer cases. 1 Great strides have
PET/CT in Breast Cancer
PET/CT in Breast Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria Overview Introduction Locorregional
Chapter 3 INCREASED PERIOPERATIVE CATECHOLAMINE EXCRETION IN PATIENTS WITH DISSEMINATED CARCINOID.
Perioperative catecholamine excretion Chapter 3 INCREASED PERIOPERATIVE CATECHOLAMINE EXCRETION IN PATIENTS WITH DISSEMINATED CARCINOID. H. de Vries 1 I.P. Kema 3 P.H.B. Willemse 2 R.C.J. Verschueren 1
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Philippe RUSZNIEWSKI
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Réunion APRAMEN, Paris, 2 février 2013 Philippe RUSZNIEWSKI Pôle des Maladies de
Ching-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
UNDERSTANDING SERIES LUNG NODULES. 1-800-298-2436 LungCancerAlliance.org
UNDERSTANDING SERIES LUNG NODULES 1-800-298-2436 LungCancerAlliance.org CONTENTS What is a Nodule?...2 Finding Nodules...3 If a Nodule is Found... 4 What Happens Next?...6 Questions to Ask about Your Results...7
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
Günter Klöppel Dept. of Pathology Consultation Center for Pancreatic and Endocrine tumors Technische Universität München
Günter Klöppel Dept. of Pathology Consultation Center for Pancreatic and Endocrine tumors Technische Universität München Incidental 1.5 cm tumor in a 45-year old man: Most probable diagnosis - Pan NEN.
Medical Applications of radiation physics. Riccardo Faccini Universita di Roma La Sapienza
Medical Applications of radiation physics Riccardo Faccini Universita di Roma La Sapienza Outlook Introduction to radiation which one? how does it interact with matter? how is it generated? Diagnostics
Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
Interview with David Djang, MD On PET Scan in Oncology: Principles and Practice
Interview with David Djang, MD On PET Scan in Oncology: Principles and Practice By Howard (Jack) West, MD May, 2009 Hello and welcome to the GRACE audio podcast on PET scanning. This one is with Dr. David
RECENT DEVELOPMENTS IN NUCLEAR MEDICINE FOR CANCER MANAGEMENT: FROM NUCLEAR MEDICINE TO MOLECULAR IMAGING
RECENT DEVELOPMENTS IN NUCLEAR MEDICINE FOR CANCER MANAGEMENT: FROM NUCLEAR MEDICINE TO MOLECULAR IMAGING A. Introduction to Molecular Imaging The last decade has witnessed significant advances in medicine,
Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans
M. Phillips, S.F. Barrington, D.L.G. Hill, P.K. Marsden 1 Comparison of Threshold-Based Segmentation Methods on Pre- and Post- Therapy PET Scans Michael Phillips 1 Michael.Phillips.1@city.ac.uk Sally F.
LUNG CANCER SCREENING: UNDERSTANDING LUNG NODULES. 1-800-298-2436 LungCancerAlliance.org
LUNG CANCER SCREENING: UNDERSTANDING LUNG NODULES 1-800-298-2436 LungCancerAlliance.org 1 1 CONTENTS What is a Nodule?...3 Finding Nodules...4 If a Nodule Is Found...5 What Happens Next?...7 Questions
Moving Beyond RECIST
Moving Beyond RECIST Ihab R. Kamel, M.D., Ph.D. ikamel@jhmi.edu Associate Professor Clinical Director, MRI Department of Radiology The Johns Hopkins University School of Medicine Outline Standard measures
This factsheet aims to outline the characteristics of some rare lung cancers, and highlight where each type of lung cancer may be different.
There are several different kinds of lung cancer, often referred to as lung cancer subtypes. Some of these occur more often than others. In this factsheet we will specifically look at the subtypes of cancers
PET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
Updates in Imaging of Advanced Prostate Cancer
Updates in Imaging of Advanced Prostate Cancer H. Alberto Vargas Director, Genitourinary Radiology Hedvig Hricak Chair, Department of Radiology New York, 16 July 2015 Nothing to disclose Outline MRI, PET/CT
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France Bone metastases 70 % of prostate and breast cancers 30 % of lung, bladder and thyroid
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Michele Klain, Marco Salvatore Department of Functional and Biomorphological Science University of Naples "Federico
Post-PET Restaging Cancer Form National Oncologic PET Registry
Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer
Seminar 7. Medical application of radioisotopes - radiotherapy
Seminar 7 Medical application of radioisotopes - radiotherapy Radioisotopes in medical diagnosis. Gamma camera. Radionuclide imaging (PET, SPECT). Radiotherapy. Sources of radiation. Treatment planning.
Us TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
CancerStemCell Markers in Lung Cancers: Proofsof. Reservations. Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany
CancerStemCell Markers in Lung Cancers: Proofsof ConceptsandSome Reservations Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany Lung cancer: highest death rate and poorest patient survival
Patterns of nodal spread in thoracic malignancies
Patterns of nodal spread in thoracic malignancies Poster No.: C-0977 Congress: ECR 2010 Type: Educational Exhibit Topic: Chest Authors: R. dos Santos, M. Duarte, J. Alpendre, J. Castaño, Z. Seabra, Â.
Long-Term Effects of Drug Addiction
Long-Term Effects of Drug Addiction Part 1: Addiction is a chronic disease Drug addiction is considered a chronic brain disease because drugs cause long-lasting changes in brain structure and function.
RADIOLOGY SERVICES. By Dr Lim Eng Kok 1
INTRODUCTION RADIOLOGY SERVICES By Dr Lim Eng Kok 1 Radiology is the branch of medicine that deals with the use of ionising (e.g. x- rays and radio-isotopes) and non-ionising radiation (e.g. ultrasound
Recommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine
Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Douglas Van Nostrand, MD, FACP, FACNM Director, Nuclear Medicine
Metastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
Lung Carcinoid Tumor
Lung Carcinoid Tumor What are lung carcinoid tumors? Lung carcinoid tumors (also known as lung carcinoids) are a type of lung cancer, which is a cancer that starts in the lungs. Cancer starts when cells
Comparison of radiation dose from X-ray, CT, and PET/ CT in paediatric patients with neuroblastoma using a dose monitoring program
Comparison of radiation dose from X-ray, CT, and PET/ CT in paediatric patients with neuroblastoma using a dose monitoring program Poster No.: C-0591 Congress: ECR 2015 Type: Authors: Keywords: DOI: Scientific
There are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine
The Clinical Trials Network of the Society of Nuclear Medicine Michael M. Graham, PhD, MD The Clinical Trials Network of the Society of Nuclear Medicine was formed to provide quality assurance of both
Sodium Fluoride PET/CT Bone Imaging: Theory and Practice
Sodium Fluoride PET/CT Bone Imaging: Theory and Practice George Segall, M.D. Stanford University Why F-18 Fluoride? Faster Higher Resolution Anatomic Correlation Chemiadsorption Hydroxyapatite Ca10(PO4)6(OH)2
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
Esperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo
Esperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo Università Campus Bio-Medico di Roma - Via Álvaro del Portillo, 21-00128 Roma Italia BED 10 > 100 Gy
Small Intestinal Neuroendocrine Tumor
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 844 Small Intestinal Neuroendocrine Tumor A Rare Malignancy with Favorable Outcome OLOV NORLÉN ACTA UNIVERSITATIS UPSALIENSIS
IAEA-TECDOC-1597. Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System
IAEA-TECDOC-1597 Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System August 2008 IAEA-TECDOC-1597 Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System
The Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
LUNG CARCINOID TUMOR. What Is Cancer? What Is a Lung Carcinoid Tumor?
LUNG CARCINOID TUMOR What Is Cancer? Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer, they all start because of out-of-control growth
Molecular Imaging in Early Phase Oncology Trials
Molecular Imaging in Early Phase Oncology Trials Lessons Learned Potential Role for SNM Network Susan Galbraith MB BChir PhD Vice-President Oncology Discovery Medicine & Clinical Biomarkers Bristol-Myers
Uso della PET nella valutazione della risposta
La diagnostica per immagini e la radioterapia: una cooperazione nel nostro futuro Uso della PET nella valutazione della risposta Cagliari, 21 giugno 2008 Arturo Chiti Medicina Nucleare, Istituto Clinico
Lung Carcinoid Tumor
Lung Carcinoid Tumor What are lung carcinoid tumors? Lung carcinoid tumors (also known as lung carcinoids) are a type of lung cancer, which is a cancer that starts in the lungs. Cancer starts when cells
Therapeutic Systems Immunology
Therapeutic Systems Immunology Coordination: Robert Preissner, Charité, Berlin 13 Partners from Berlin (7) Göttingen (1) Heidelberg (1) Rostock (2) Tübingen (1) Overview Intro / Mission Partners Systems
Dr. Lengyel Zsolt. Budapest. Worldnumbers.com: PET and PET/CT Are the Fastest Growing Imaging Modalities Worldwide
Worldnumbers.com: PET and PET/CT re the Fastest Growing Imaging Modalities Worldwide Dr. Lengyel Zsolt Budapest ENM: PET and PET/CT scans grow by 21% a year The development of PET and PET/CT examinations
Neuroendocrin tumors, GIST, cancer of unknown primary. Renal neoplasms.
Neuroendocrin tumors, GIST, cancer of unknown primary. Renal neoplasms. Ibolya Czegle MD PhD Semmelweis University 3rd Deparment of Internal Medicine, Oncology Center Neuroendocrin tumors Gastroenteropancreatic
Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
Releasing Nuclear Medicine Patients to the Public: Dose Calculations and Discharge Instructions
Educational Objectives Releasing Nuclear Medicine Patients to the Public: Dose Calculations and Discharge Instructions Robert E. Reiman, MD Radiation Safety Division Duke University Medical Center Durham,
Pacific Northwest Society of Pathologists
Pacific Northwest Society of Pathologists Activity Title: 2009 Spring Meeting Location: Fred Hutchinson Cancer Research Center, Seattle, WA Objectives for this Session Understand the history of medical
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
Barry L Shulkin, MD MBA St. Jude Children s Research Hospital Memphis, TN
I-131 MIBG for Therapy of Neuroblastoma Barry L Shulkin, MD MBA St. Jude Children s Research Hospital Memphis, TN Functional Imaging of Neuroblastoma Barry L. Shulkin MD MBA St. Jude Children s Research
Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment.
Dictionary Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment. Applicator A device used to hold a radioactive source
Positron Emission Tomography: Principles, Technology, and Recent Developments
Nuclear Physics A 752 (2005) 679c 687c Positron Emission Tomography: Principles, Technology, and Recent Developments Sibylle I. Ziegler Nuklearmedizinische Klinik, Klinikum rechts der Isar der Technischen
Inclusion of Biological Information in Treatment Planning Optimization Dag Rune Olsen
Inclusion of Biological Information in Treatment Planning Optimization Dag Rune Olsen Institute for Cancer Research, Norwegian Radium Hospital, University of Oslo Theragnostics biological conformality
THYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
The Medical Imaging Detective
Solving Medical Mysteries with Imaging Richard S. Breiman, M.D. Professor of Radiology and Biomedical Imaging (Medical Imaging Detective) UCSF The Medical Imaging Detective Peering into the Patient to
General Nuclear Medicine
Scan for mobile link. General Nuclear Medicine Nuclear medicine imaging uses small amounts of radioactive materials called radiotracers that are typically injected into the bloodstream, inhaled or swallowed.
Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
Low-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
The best for life. To nejlepší pro život. Advanced Cancer Treatment
The best for life. To nejlepší pro život. Advanced Cancer Treatment Proton therapy is a highly advanced and effective treatment of malignant tumors. Proton therapy offers a low risk of complications during
This handout is for informational purposes only. Talk with your doctor or health care team if you have any questions about your care.
PATIENT EDUCATION patienteducation.osumc.edu PET stands for Positron Emission Tomography. The scan looks at metabolic activity (cell activity) inside the body. Your doctor uses this information to help
A new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
INQUADRAMENTO DIAGNOSTICO DEI TUMORI NEUROENDOCRINI DEL PANCREAS. Maria Rosaria Ambrosio. Università degli Studi di Ferrara
INQUADRAMENTO DIAGNOSTICO DEI TUMORI NEUROENDOCRINI DEL PANCREAS Maria Rosaria Ambrosio Università degli Studi di Ferrara Dipartimento di Scienze Mediche Sezione di Endocrinologia Direttore Prof. Ettore
Loma Linda University and Siemens PETNET Solutions, Inc.
Loma Linda University and Siemens PETNET Solutions, Inc. announce operational state-of-theart PET production and research facility to advance molecular imaging FOR IMMEDIATE RELEASE CONTACT: Susan Onuma
Pathways. The CTN Oncology Phantom Program: Evaluating 6 Years of Scanner Performance Data. Since 2008, the Clinical Trials Network.
JUNE 2015 Pathways THE CLINICAL TRIALS NETWORK NEWSLETTER Table of Contents 2 Standardization: Keeping Pace with Technology 3 CMS Approves IDEAS Study CTN Highlights: SNMMI 2015 AM 4 Quantitative Results
Mississippi Medicaid. Provider Reference Guide. For Part 220. Radiology Services
Mississippi Medicaid Provider Reference Guide For Part 220 Radiology Services This is a companion document to the Mississippi Administrative Code Title 23 and must be utilized as a reference only. Table
Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
Positron Emission Tomography - For Patients
Positron Emission Tomography - For Patients A physician s written order is required for any PET-CT tests. How should I prepare for my PET-CT? PET-CT is more complicated than most other tests you may be
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
The Science behind Proton Beam Therapy
The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related
Describe how these hormones exert control quickly by changes in phosphorylation state of enzyme, and more slowly by changes of gene expression
Section VIII. Section VIII. Tissue metabolism Many tissues carry out specialized functions: Ch. 43 look at different hormones affect metabolism of fuels, especially counter-insulin Ch. 44 Proteins and
Cancer Therapy with Particle Beams
Cancer Therapy with Particle Beams The potential to use high energy particle beams to treat many types of cancer has been known even before their creation. The availability of these treatments has been
Society of Nuclear Medicine Procedure Guideline for Somatostatin Receptor Scintigraphy with In-111 Pentetreotide
Society of Nuclear Medicine Procedure Guideline for Somatostatin Receptor Scintigraphy with In-111 Pentetreotide version 1.0, approved February 21, 2001 Authors: Helena R. Balon, MD (William Beaumont Hospital,
General Information About Non-Small Cell Lung Cancer
General Information About Non-Small Cell Lung Cancer Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing